In total , 60 patients were randomized and 58 received 1 study medication dose ( all-treated ) , 31 patients fulfilled inclusion/exclusion and continuation criteria ( all-treated target [ ATT ] ) ( telavancin 15 , standard therapy 16 ) , and 17 patients were clinically evaluable ( CE ) ( telavancin 8 , standard therapy 9 ) .